Yulia Vugmeyster
Merck (Germany)(DE)Merck Serono (Italy)(IT)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Monoclonal and Polyclonal Antibodies Research, Endometrial and Cervical Cancer Treatments, Sarcoma Diagnosis and Treatment, T-cell and B-cell Immunology
Most-Cited Works
- → Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges(2012)241 cited
- → Major histocompatibility complex (MHC) class I KbDb−/− deficient mice possess functional CD8+ T cells and natural killer cells(1998)124 cited
- → Peptide Antagonism and T Cell Receptor Interactions with Peptide-MHC Complexes(1998)116 cited
- → Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain(2012)86 cited
- → Depletion of B Cells by a Humanized Anti-CD20 Antibody PRO70769 in Macaca Fascicularis(2005)79 cited
- → Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno‐Oncology and Beyond: Challenges, Perspectives, and Prospects(2020)78 cited
- → A Soluble BAFF Antagonist, BR3-Fc, Decreases Peripheral Blood B Cells and Lymphoid Tissue Marginal Zone and Follicular B Cells in Cynomolgus Monkeys(2006)78 cited
- → Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial(2023)76 cited
- → Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma(2019)74 cited
- → Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin(2004)72 cited